Price T Rowe Associates Inc. MD Cuts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

Price T Rowe Associates Inc. MD reduced its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 39.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 909,707 shares of the company's stock after selling 604,798 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.25% of Keros Therapeutics worth $14,402,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in shares of Keros Therapeutics by 1,149.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 22,984 shares of the company's stock worth $364,000 after purchasing an additional 21,145 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Keros Therapeutics by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock worth $286,000 after buying an additional 1,027 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Keros Therapeutics by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 155,163 shares of the company's stock valued at $2,456,000 after buying an additional 2,727 shares in the last quarter. Altium Capital Management LLC grew its position in Keros Therapeutics by 153.6% in the fourth quarter. Altium Capital Management LLC now owns 175,000 shares of the company's stock worth $2,770,000 after acquiring an additional 106,000 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in Keros Therapeutics by 207.8% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after purchasing an additional 4,976 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 22.90% of the company's stock.

Keros Therapeutics Stock Performance

Shares of KROS traded up $0.03 on Thursday, hitting $13.74. 125,463 shares of the stock traded hands, compared to its average volume of 814,817. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The company has a market capitalization of $558.00 million, a PE ratio of -2.64 and a beta of 1.32. The business has a 50 day simple moving average of $12.10 and a 200 day simple moving average of $25.34.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the prior year, the firm earned ($1.21) earnings per share. On average, equities analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on KROS. HC Wainwright decreased their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday. Piper Sandler dropped their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Guggenheim reiterated a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. Finally, Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $38.67.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.